Citation: D. Elliman et H. Bedford, MMR vaccine: the continuing saga - Current concerns are idiosyncratic: most reviews have confirmed the vaccine's safety, BR MED J, 322(7280), 2001, pp. 183-184
Citation: D. Elliman et H. Bedford, MMR immunisation - Health professionals should strongly recommend this immunisation, BR MED J, 323(7317), 2001, pp. 869-869
Authors:
Richardson, M
Elliman, D
Maguire, H
Simpson, J
Nicoll, A
Citation: M. Richardson et al., Evidence base of incubation periods, periods of infectiousness and exclusion policies for the control of communicable diseases in schools and preschools, PEDIAT INF, 20(4), 2001, pp. 380-391
Authors:
Bramley, JC
Hall, T
Finn, A
Buttery, RB
Elliman, D
Lockhart, S
Borrow, R
Jones, IG
Citation: Jc. Bramley et al., Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age, VACCINE, 19(20-22), 2001, pp. 2924-2931
Authors:
Rahi, JS
Williams, C
Bedford, H
Elliman, D
Citation: Js. Rahi et al., Screening and surveillance for ophthalmic disorders and visual deficits inchildren in the United Kingdom, BR J OPHTH, 85(3), 2001, pp. 257-259
Citation: D. Elliman et H. Bedford, Perhaps it is not time to switch from whole cell to acellular pertussis vaccine, BR MED J, 321(7258), 2000, pp. 451-452
Citation: H. Bedford et D. Elliman, Studies of adverse effects of vaccination have duty to present full picture, BR MED J, 318(7196), 1999, pp. 1487-1487
Citation: D. Elliman, Vaccination and type 1 diabetes mellitus - Currently no evidence of a linkbut more studies are needed as vaccines change, BR MED J, 318(7192), 1999, pp. 1159-1160